Clinical trials
HR+ Breast Cancer clinical trials
Below are recruiting hr+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 329 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT07671885RecruitingPhase 3
Hormone therapy before surgery for premenopausal breast cancer
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
AkitaAges 18 years+ - NCT06611813RecruitingPhase 2
Chemo plus immunotherapy for HR+/HER2- breast cancer
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
HangzhouAges 18–75 - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06642545RecruitingPhase 2
New targeted drug combo for HER2-low breast cancer
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06649331RecruitingPhase 2
Re-trying antibody-drug conjugates for advanced breast cancer
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06650423Recruiting
Staying on hormone therapy for early breast cancer
This study looks at how well patients take their hormone-lowering pills (aromatase inhibitors, with or without abemaciclib) for early-stage breast cancer. It aims to understand adherence patterns and help improve support for patients.
LjubljanaAges 18–99 - NCT06678048RecruitingPhase 2
Arsenous acid for hard-to-treat triple-negative breast cancer
This trial tests a medicine called arsenous acid for people with triple-negative breast cancer that has not responded to at least two prior treatments. If you join, you will get arsenous acid plus one of four chemotherapy drugs to see if the combination can shrink tumors.
Guangzhou, GuangdongAges 18–75 - NCT04968964Recruiting
Monitoring test for CDK4/6 drugs in metastatic breast cancer
This study follows people with hormone receptor–positive, HER2-negative metastatic breast cancer who are taking CDK4/6 inhibitor treatment (with or without an added blood test called DiviTum®). The goal is to see how well the standard treatment is working and whether DiviTum® (a serum TK1 activity test) can help guide monitoring.
St Louis, MissouriAges 18 years+ - NCT06738966RecruitingPhase 1
BL0175 for advanced HR-positive breast or gynecologic cancer
This trial tests a new drug called BL0175 for women with certain types of advanced breast, ovarian, or endometrial cancer that have stopped responding to hormone therapy. The goal is to see if the drug can help shrink tumors or slow down the cancer.
Changchun, JilinAges 18 years+ - NCT06756932RecruitingPhase 1
Bcl-2 inhibitor combo for advanced HR+ breast cancer
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Iowa City, IowaAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Duarte, CaliforniaAges 18 years+ - NCT06762483Recruiting
Blood test for gene changes in advanced breast cancer
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Milan, ItalyAges 18 years+ - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06781996RecruitingPhase 3
Digital tool to help manage hormone therapy side effects
This trial tests a digital tool (a smartphone app) to help women and men with early breast cancer manage side effects from hormone therapy. The goal is to improve quality of life during treatment.
VillejuifAges 18 years+ - NCT06797531Recruiting
Ribociclib Real-World Study in Early Breast Cancer
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
RiyadhAges 18–99 - NCT06797635RecruitingPhase 2
Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Santa Monica, CaliforniaAges 18 years+ - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT06833502RecruitingPhase 2
Screening for breast cancer spread after chemo and surgery
This trial aims to find out if doing special scans to check for breast cancer spread to organs (not just lymph nodes) is helpful in certain patients. The study looks at people with breast cancer that had already spread to lymph nodes and did not completely go away with chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT06874933RecruitingPhase 2
Chemo plus anlotinib and benmelstobart for HR+/HER2- breast cancer
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
Hangzhou, ZhejiangAges 18–75 - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Daphne, AlabamaAges 18 years+ - NCT06967103RecruitingPhase 2
New drug before breast cancer surgery
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
ZhengzhouAges 18 years+ - NCT06977893RecruitingPhase 3
Chemo and immunotherapy for HR+ breast cancer before surgery
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
HangzhouAges 18–75 - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hr+ breast cancer?
- Yes. Clin2 currently lists 329 recruiting hr+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hr+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hr+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.